# Efficacy and Safety on SOM3355 in Huntington's Disease Chorea

> **NCT05475483** · PHASE2 · COMPLETED · sponsor: **SOM Innovation Biotech SA** · enrollment: 139 (actual)

## Conditions studied

- Huntington Chorea

## Interventions

- **DRUG:** Placebo capsules
- **DRUG:** SOM3355 200 mg capsules
- **DRUG:** SOM3355 300 mg capsules

## Key facts

- **NCT ID:** NCT05475483
- **Lead sponsor:** SOM Innovation Biotech SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-02
- **Primary completion:** 2024-06-25
- **Final completion:** 2024-07-15
- **Target enrollment:** 139 (ACTUAL)
- **Last updated:** 2025-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05475483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05475483, "Efficacy and Safety on SOM3355 in Huntington's Disease Chorea". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05475483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*